Please assess the completion status of the following clinical trial:

Trial Title: Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically documented pancreatic adenocarcinoma deemed unresectable due to local involvement of vessels or organs~* Patients with a clear clinical diagnosis of localized pancreatic cancer deemed unresectable, who have undergone at least 2 biopsies which were not diagnostic of adenocarcinoma, may be entered at the discretion of the principal investigator.~* No prior chemotherapy or abdominal radiation therapy.~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1~* Clinically measurable or evaluable disease.~* Life expectancy of at least 12 weeks.~* Adequate bone marrow reserve, granulocyte count \>= 1500/uL, platelet count \>= 100,000/uL, hemoglobin \>= 9 g/dL.~* Adequate renal function with creatinine =\< 1.5 times upper limit of normal (ULN)~* Adequate biliary function with bilirubin \< 3.0 g/dL (including patients who have been bypassed or treated with percutaneous drainage), serum glutamic pyruvic transaminase (SGPT) (alanine transaminase) =\< 2.5~* Age \> 18 years~* Signed informed consent.~* No known allergy to one of the study drugs~* For female patient of childbearing potential, neither pregnant nor breastfeeding, and under active contraception~* No prior malignancy within last 5 years~* No central nervous system metastases~* No peripheral neuropathy \> grade2~* No other serious concomitant illness~Exclusion Criteria:~* Active infection or uncontrolled infection~* Presence of metastatic disease.~* Inadequate organ function as discussed above.~* Pregnancy~* Serious concomitant systemic disorder.~* Use of any investigational agent within a month of treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oxaliplatin+ 5FU+ radiation (RT) /surgery /FOLFOX 6 (Type: EXPERIMENTAL): Concurrent chemoradiation before surgery and FOLFOX6 regimen after surgery~Radiation (RT) 180cGy daily x 5 days/week x 5 weeks, then additional 540 cGy in 3 fractions over a half week to pancreatic portal;~Combined with :~5FU 200 mg/m\^2 daily by continuous intravenous infusion (CIV) x 5 weeks and weekly Oxaliplatin 60 mg/m\^2, IV for 5 weeks (in Phase I, 30, 40, 50, and 60 mg/m\^2 Oxaliplatin were tested).~Observation for 2 weeks to assess dose-limiting toxicity (DLT)/Response. Surgery if deemed resectable.~Then modified FOLFOX 6 for 6 cycles (2 weeks/cycle):~Day 1 hour 0: Oxaliplatin 85 mg/m\^2 intravenously (IV) + Leucovorin 350 mg IV over 2 hours; hour 2: 5FU 400 mg/m\^2 IV bolus followed by 2400 mg/m\^2 IV over 46 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).